Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
73 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Fracture - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Fracture - Pipeline Review, H2 2014', provides an overview of the Fracture's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Fracture, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fracture and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Fracture - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Fracture and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Fracture products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Fracture pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Fracture - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Fracture pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Fracture Overview 8 Therapeutics Development 9 Pipeline Products for Fracture - Overview 9 Pipeline Products for Fracture - Comparative Analysis 10 Fracture - Therapeutics under Development by Companies 11 Fracture - Therapeutics under Investigation by Universities/Institutes 13 Fracture - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Fracture - Products under Development by Companies 17 Fracture - Products under Investigation by Universities/Institutes 18 Fracture - Companies Involved in Therapeutics Development 19 Eli Lilly and Company 19 Kuros Biosurgery AG 20 Novartis AG 21 Kolon Life Science, Inc. 22 TissueGene, Inc. 23 Radius Health, Inc. 24 Arcarios BV 25 Escape Therapeutics, Inc. 26 OrgaNext Research BV 27 Fracture - Therapeutics Assessment 28 Assessment by Monotherapy Products 28 Assessment by Combination Products 29 Assessment by Target 30 Assessment by Mechanism of Action 32 Assessment by Route of Administration 34 Assessment by Molecule Type 36 Drug Profiles 38 teriparatide - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 abaloparatide - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 KUR-113 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 bimagrumab - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 (nandrolone decanoate + cholecalciferol) - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 rusalatide acetate - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 KLS-Bfr - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 OsteoStem - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 TG-B - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Stromal Cell Therapy For Fracture Repair - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Bone Morphogenetic Protein Modulators - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Small Molecules for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Small Molecules for Immunology, Musculoskeletal and Metabolic Disorders - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Fracture - Recent Pipeline Updates 58 Fracture - Dormant Projects 62 Fracture - Discontinued Products 63 Fracture - Product Development Milestones 64 Featured News & Press Releases 64 Mar 11, 2013: Merck Provides Update On Fosamax Product Liability Trial 64 Feb 11, 2013: UCB And Amgen Decide Not To Pursue Phase III Clinical Trial Program For CDP7851 64 Jan 07, 2013: Radius Provides Update On Pivotal Phase III Program For BA058-SC Injection 65 Oct 15, 2012: Daiichi Sankyo Announces Positive Phase III Study Results For Denosumab On Fracture Risk In Japanese Patients With Osteoporosis At ASBMR 65 Aug 07, 2012: Lilly Announces Study Results Regarding Postmenopausal Women With Back Pain Caused By Vertebral Fractures 66 Jan 24, 2011: Kuros Reports One Year Data From Phase IIb Study With KUR-111 67 Jun 02, 2010: Kuros Completes Patient Recruitment In A Phase IIB Trial Of KUR-113 In Patients With Tibial Shaft Fractures 68 Jun 01, 2010: Amgen Receives FDA Approval For Prolia For Treatment Of Postmenopausal Women With Osteoporosis At High Risk For Fracture 69 Mar 15, 2010: Kuros Meets Primary Efficacy Endpoint In Phase IIb Study With KUR-111 70 Jun 08, 2009: Kuros Completes Patient Recruitment In A Phase IIb Trial Of KUR-111 In Patients With Tibial Plateau Fractures 71 Appendix 72 Methodology 72 Coverage 72 Secondary Research 72 Primary Research 72 Expert Panel Validation 72 Contact Us 73 Disclaimer 73
List of Tables Number of Products under Development for Fracture, H2 2014 9 Number of Products under Development for Fracture - Comparative Analysis, H2 2014 10 Number of Products under Development by Companies, H2 2014 12 Number of Products under Investigation by Universities/Institutes, H2 2014 13 Comparative Analysis by Late Stage Development, H2 2014 14 Comparative Analysis by Clinical Stage Development, H2 2014 15 Comparative Analysis by Early Stage Development, H2 2014 16 Products under Development by Companies, H2 2014 17 Products under Investigation by Universities/Institutes, H2 2014 18 Fracture - Pipeline by Eli Lilly and Company, H2 2014 19 Fracture - Pipeline by Kuros Biosurgery AG, H2 2014 20 Fracture - Pipeline by Novartis AG, H2 2014 21 Fracture - Pipeline by Kolon Life Science, Inc., H2 2014 22 Fracture - Pipeline by TissueGene, Inc., H2 2014 23 Fracture - Pipeline by Radius Health, Inc., H2 2014 24 Fracture - Pipeline by Arcarios BV, H2 2014 25 Fracture - Pipeline by Escape Therapeutics, Inc., H2 2014 26 Fracture - Pipeline by OrgaNext Research BV, H2 2014 27 Assessment by Monotherapy Products, H2 2014 28 Assessment by Combination Products, H2 2014 29 Number of Products by Stage and Target, H2 2014 31 Number of Products by Stage and Mechanism of Action, H2 2014 33 Number of Products by Stage and Route of Administration, H2 2014 35 Number of Products by Stage and Molecule Type, H2 2014 37 Fracture Therapeutics - Recent Pipeline Updates, H2 2014 58 Fracture - Dormant Projects, H2 2014 62 Fracture - Discontinued Products, H2 2014 63
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
